China Biotech Services Holdings Limited

SEHK:8037 Stock Report

Market Cap: HK$429.3m

China Biotech Services Holdings Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for China Biotech Services Holdings.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth18.5%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

China Biotech Services Holdings Limited's (HKG:8037) 28% Share Price Plunge Could Signal Some Risk

Aug 12
China Biotech Services Holdings Limited's (HKG:8037) 28% Share Price Plunge Could Signal Some Risk

Some Shareholders Feeling Restless Over China Biotech Services Holdings Limited's (HKG:8037) P/S Ratio

Jun 26
Some Shareholders Feeling Restless Over China Biotech Services Holdings Limited's (HKG:8037) P/S Ratio

China Biotech Services Holdings Limited's (HKG:8037) Popularity With Investors Under Threat As Stock Sinks 31%

Mar 07
China Biotech Services Holdings Limited's (HKG:8037) Popularity With Investors Under Threat As Stock Sinks 31%

Earnings Not Telling The Story For China Biotech Services Holdings Limited (HKG:8037) After Shares Rise 46%

Jan 18
Earnings Not Telling The Story For China Biotech Services Holdings Limited (HKG:8037) After Shares Rise 46%

We Think China Biotech Services Holdings (HKG:8037) Might Have The DNA Of A Multi-Bagger

Jan 06
We Think China Biotech Services Holdings (HKG:8037) Might Have The DNA Of A Multi-Bagger

Does China Biotech Services Holdings (HKG:8037) Have A Healthy Balance Sheet?

Dec 09
Does China Biotech Services Holdings (HKG:8037) Have A Healthy Balance Sheet?

These 4 Measures Indicate That China Biotech Services Holdings (HKG:8037) Is Using Debt Safely

Aug 24
These 4 Measures Indicate That China Biotech Services Holdings (HKG:8037) Is Using Debt Safely

A Look At The Fair Value Of China Biotech Services Holdings Limited (HKG:8037)

Nov 05
A Look At The Fair Value Of China Biotech Services Holdings Limited (HKG:8037)

Is China Biotech Services Holdings (HKG:8037) A Risky Investment?

Oct 13
Is China Biotech Services Holdings (HKG:8037) A Risky Investment?

What China Biotech Services Holdings Limited's (HKG:8037) 35% Share Price Gain Is Not Telling You

Jun 28
What China Biotech Services Holdings Limited's (HKG:8037) 35% Share Price Gain Is Not Telling You

China Biotech Services Holdings (HKG:8037) Could Become A Multi-Bagger

Mar 16
China Biotech Services Holdings (HKG:8037) Could Become A Multi-Bagger

China Biotech Services Holdings (HKG:8037) Knows How To Allocate Capital Effectively

Dec 01
China Biotech Services Holdings (HKG:8037) Knows How To Allocate Capital Effectively

Under The Bonnet, China Biotech Services Holdings' (HKG:8037) Returns Look Impressive

Jul 26
Under The Bonnet, China Biotech Services Holdings' (HKG:8037) Returns Look Impressive

China Biotech Services Holdings' (HKG:8037) Robust Earnings Are Supported By Other Strong Factors

Apr 05
China Biotech Services Holdings' (HKG:8037) Robust Earnings Are Supported By Other Strong Factors

Investors Shouldn't Overlook China Biotech Services Holdings' (HKG:8037) Impressive Returns On Capital

Mar 23
Investors Shouldn't Overlook China Biotech Services Holdings' (HKG:8037) Impressive Returns On Capital

Did You Miss China Biotech Services Holdings' (HKG:8037) Whopping 825% Share Price Gain?

Feb 23
Did You Miss China Biotech Services Holdings' (HKG:8037) Whopping 825% Share Price Gain?

Chun-Shun Ko Just Bought 27% More Shares In China Biotech Services Holdings Limited (HKG:8037)

Jan 28
Chun-Shun Ko Just Bought 27% More Shares In China Biotech Services Holdings Limited (HKG:8037)

What Is The Ownership Structure Like For China Biotech Services Holdings Limited (HKG:8037)?

Jan 11
What Is The Ownership Structure Like For China Biotech Services Holdings Limited (HKG:8037)?

The Trend Of High Returns At China Biotech Services Holdings (HKG:8037) Has Us Very Interested

Dec 08
The Trend Of High Returns At China Biotech Services Holdings (HKG:8037) Has Us Very Interested

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China Biotech Services Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:8037 - Analysts future estimates and past financials data (HKD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/202462-145-419-211N/A
3/31/202498-120N/AN/AN/A
12/31/2023212-95132195N/A
9/30/202377633N/AN/AN/A
6/30/20231,347159513610N/A
3/31/20231,598208N/AN/AN/A
12/31/20221,852258375483N/A
9/30/20221,39474N/AN/AN/A
6/30/20229373222257N/A
3/31/202285453N/AN/AN/A
12/31/2021624192841N/A
9/30/2021614113N/AN/AN/A
6/30/2021999155296426N/A
3/31/202179754N/AN/AN/A
12/31/202065630295422N/A
9/30/2020564-21N/AN/AN/A
6/30/202062-105-57-50N/A
3/31/202058-106N/AN/AN/A
12/31/201959-99-38-30N/A
9/30/201962-76N/AN/AN/A
6/30/201965-72-38-34N/A
3/31/201967-66N/AN/AN/A
12/31/201870-64-21-15N/A
9/30/201875-95N/AN/AN/A
6/30/201879-83-45-40N/A
3/31/201888-48N/AN/AN/A
12/31/2017105-63N/A-57N/A
9/30/2017111-48N/AN/AN/A
6/30/2017113-64N/A-11N/A
3/31/2017104-103N/AN/AN/A
12/31/201687-86N/A-25N/A
9/30/201669-81N/AN/AN/A
6/30/201652-84N/A-90N/A
3/31/201639-72N/AN/AN/A
12/31/201534-54N/A-85N/A
9/30/20153-36N/AN/AN/A
6/30/201538-21N/A-19N/A
3/31/201556-43N/AN/AN/A
12/31/201470-75N/A-40N/A
9/30/2014111-85N/AN/AN/A
6/30/201492-84N/A-78N/A
3/31/201489-79N/AN/AN/A
12/31/201385-60N/A-42N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 8037's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 8037's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 8037's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 8037's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 8037's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 8037's Return on Equity is forecast to be high in 3 years time


Discover growth companies